TAG72-CAR T / City of Hope - LARVOL DELTA

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: City of Hope Medical Center | Trial primary completion date: Apr 2026 ➔ Dec 2026

Trial primary completion date • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

City of Hope researchers develop a CAR T cell therapy for advanced ovarian cancer (PRNewswire) - "Researchers with City of Hope, one of the largest cancer research and treatment organizations in the nation, have published preclinical research in Nature Communications demonstrating that a chimeric antigen receptor (CAR)-engineered T cell therapy worked against ovarian cancer in the laboratory and in preclinical models....The team's most recent research found that a CAR T cell therapy targeting TAG72, a target found on the surface of ovarian cancer cells, eradicates cancer cells in mouse models."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Effective Targeting of Gastric Cancer Peritoneal Metastases with Cytokine-Endowed TAG72-Directed CAR T Cells (ASGCT 2023) - "Molecular heterogeneity of GC and poor immunogenicity of peritoneal immune tumor microenvironment (TME) limit the benefits of existing immunotherapeutic strategies that include trastuzumab (anti-HER2), ramucirumab (anti-VEGF), pembrolizumab, and nivolumab (anti-PD-1). Additionally, our newly engineered TAG72-CAR T cells with a membrane-bound version of the IL-12 (mbIL12) cytokine significantly enhanced anti-tumor efficacy of TAG72-CAR T cells leading to more durable in vivo therapeutic responses. A novel immunotherapeutic combination using autologous mbIL12-engineered TAG72-CAR T cell therapy is a promising strategy to help overcome the therapeutic failures in GCPM patients."

CAR T-Cell Therapy • IO biomarker • Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor • IL12A • TAG-72

Engineering TAG72-CAR T cells as a therapeutic strategy in the hen - a spontaneous, preclinical model for ovarian cancer (AACR 2023) - "In this study, chicken TAG72-CAR T cells were successfully generated, characterized, and tested as a therapeutic approach for treating OvCa in the hen, and will be further used to evaluate their in vivo efficacy in the hen model. The ability to test therapeutic strategies in an in vivo model that biologically and physiologically parallels the disease in women allows for the improvement of OvCa diagnosis and prognosis."

CAR T-Cell Therapy • Preclinical • Oncology • Ovarian Cancer • Solid Tumor • TAG-72

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Nov 2026 ➔ Apr 2027 | Trial primary completion date: Nov 2025 ➔ Apr 2026

CAR T-Cell Therapy • Immune cell • Metastases • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • BRCA • HRD • IFNG • IL10 • TNFA

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2024 ➔ Nov 2026 | Trial primary completion date: Dec 2024 ➔ Nov 2025

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Oncology • Ovarian Cancer • Solid Tumor • BRCA • HRD • IFNG • IL10 • TNFA

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Oncology • Ovarian Cancer • Solid Tumor • BRCA • HRD • IFNG • IL10 • TNFA